Blue Helix Health is set to present its research on NAD+ and mitochondrial function at the upcoming international NAD for Health conference in Copenhagen. Mathias Ziegler, Professor of Biomedicine at the University of Bergen and Chief Scientific Officer of Blue Helix Health, will showcase clinical evidence supporting the efficacy of their BluNADBooster ingredient, which aims to enhance NAD+ levels in the body.

This presentation is significant for the longevity and healthspan field as it underscores the growing interest in NAD+ as a therapeutic target for age-related decline. The focus on mitochondrial health is particularly relevant, given its critical role in cellular energy production and overall metabolic function. As researchers and companies explore innovative ways to boost NAD+ levels, findings from this conference could inform future therapeutic strategies and product development.

For professionals in the field, the key takeaway is the importance of NAD+ research in the context of aging and healthspan, highlighting potential avenues for intervention and the increasing relevance of nutraceuticals in addressing age-related health challenges.

Source: nutraceuticalbusinessreview.com